Latest Breaking News On - Tay sachs diseases - Page 1 : comparemela.com

Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients

Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomAsahi kasei pharmaAmber fennellAshley tappChris freitagRoberto giuglianiPorto alegreLeiden universityDrug administrationEuropean medicines agencyGenetics clinical research groupHealthcare products regulatory agencyMedical genetics clinical research groupHospital de clinicas porto alegreLead principal investigator

Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium™

Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium™
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoUnited kingdomAsahi kasei pharmaChristian freitagLeiden universityHealthcare products regulatory agencyEuropean medicines agencyDrug administrationMolecular geneticsLysosomal storageChief medical officerStates foodPediatric disease designationsDrug designationsTay sachs diseases

Azafaros Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled

Azafaros Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesRoberto giuglianiPorto alegreDrug administrationGenetics serviceLeiden universityEuropean medicines agencyHealthcare products regulatory agencyMedical genetics serviceHospital clinicas de porto alegreLead principal investigatorDaniel almeidaStefano portolanoRare pediatric disease designationsUnited states food

Azafaros Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled

Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolledTopline data from the study, exp.

United kingdomUnited statesPorto alegreRoberto giuglianiLeiden universityEuropean medicines agencyDrug administrationHealthcare products regulatory agencyGenetics serviceAzafaro phaseMedical genetics serviceHospital clinicas de porto alegreLead principal investigatorDaniel almeidaStefano portolanoRare pediatric disease designations

Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients

RAINBOW study design enables rapid advancement into the company's planned Phase 3 efficacy trial Azafaros B.V. today announced that the first patient has been enrolled into its Phase 2 RAINBOW

Mecklenburg vorpommernUnited statesUnited kingdomGretchen schweitzerPorto alegreMarie theresa weickertStefan klotterRoberto giuglianiHealthcare products regulatory agencyTrophic communicationsDrug administrationLeiden universityEuropean medicines agencyGenetics clinical research groupDaniel almeidaPaediatric neurologist